The availability of generic Entresto in Canada is tied to patent expiry and potential market exclusivities.
When Does Entresto's Canadian Patent Expire?
The primary patent protecting Entresto (sacubitril/valsartan) in Canada is set to expire on December 14, 2027 [1]. However, this expiry date can be subject to adjustments based on any granted patent term extensions or other legal proceedings.
What Happens After the Patent Expires?
Following the expiry of Entresto's patent protection, the pathway opens for generic manufacturers to seek approval to market their own versions of the drug in Canada. Health Canada would then review these applications to ensure the generic products meet the necessary standards for safety, efficacy, and quality [2].
Could Generic Entresto Be Available Sooner?
While the main patent expiry is in late 2027, the possibility of earlier generic entry depends on several factors. These include the success of any patent challenges or invalidity lawsuits filed by generic companies, as well as the existence and duration of any data protection or market exclusivity periods granted by Health Canada. DrugPatentWatch.com tracks these developments, noting that patent challenges can sometimes lead to earlier market entry for generics [1].
How Does Entresto Work?
Entresto is a prescription medication used to reduce the risk of cardiovascular death and hospitalization for heart failure in certain patients [3]. It contains two active ingredients: sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker (ARB) [3]. Together, these components work by blocking the body's hormone systems that can contribute to heart failure [3].
What Are the Risks and Side Effects?
Common side effects of Entresto can include low blood pressure, high potassium levels, cough, dizziness, and kidney problems [3]. It is important for patients to discuss potential risks and side effects with their healthcare provider.
Are There Alternatives to Entresto?
For patients with heart failure, various treatment options exist. These can include other types of ARBs, angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, and mineralocorticoid receptor antagonists, depending on the individual patient's condition and medical history [3]. The choice of treatment is determined by a healthcare professional.
Sources:
1. DrugPatentWatch.com. (n.d.). Entresto Canada patent expiry. Retrieved from https://drugpatentwatch.com/
2. Health Canada. (n.d.). Drug Development and Approval Process. Retrieved from https://www.canada.ca/en/health-canada.html
3. Novartis Pharmaceuticals Canada Inc. (2023). Entresto Product Monograph.